SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of
Investors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK, Nov. 13, 2013
NEW YORK, Nov. 13, 2013 /PRNewswire/ --Pomerantz Grossman Hufford Dahlstrom &
Gross LLP is investigating claims on behalf of investors of Sarepta
Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such
investors are advised to contact Robert S. Willoughby at
email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Sarepta and certain of its officers and/or
directors have violated Sections 10(b) and 20(a) of the Securities Exchange
Act of 1934. On November 11, 2013, shares of Sarepta declined sharply after
the Company announced that it was told by the Food and Drug Administration,
(FDA) not to file for accelerated approval of eteplirsen, Sarepta's
pharmaceutical to treat Duchenne muscular dystrophy.
On this news, shares of Sarepta fell $23.40 per share, more than 64.00%, on
intraday trading, to a price of $13.16 on November 11, 2013.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Press spacebar to pause and continue. Press esc to stop.